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Abstract 
Introduction: Allostatic load (AL) index proposes indicators for the func-
tioning of the main potentially stress-affected systems. Sex differences in 
stress response and stress-related diseases susceptibility have been described 
for the general population. In this observational study we describe the effects 
of sex and age on AL variables, in a cohort of patients with general anxiety 
disorders and neuroticism treated with alprazolam during 12 weeks, before 
and after treatment. Methods: Patients with general (DSM IV) anxiety disor-
ders with >6 in Hamilton scale, AL (>1 Crimmins and Seeman AL modified 
criteria) and neuroticism >18 (NEO-FFI inventory), were included. All pa-
tients completed psychiatric assessment, AL index determination before (−1 
week) and after 12 weeks of treatment with alprazolam (0.25 - 1 mg/t.i.d). Al-
lostatic load parameters comprised cardiovascular, metabolic and inflamma-
tory variables. Univariate analysis (two-way ANOVA), Student’s t-test (re-
lated variables) and Pearson correlations were determined. Results: Fifty-four 
patients, 35 females (48.6 ± 11.7 years) and 19 males (44.2 ± 12.8 years) with 
general anxiety disorder were included; 28 patients with <50 years (60.7% fe-
males), and 26 with ≥50 years (69.2% females). Younger patients (<50 years) 
(two-way ANOVA, p = 0.02) were significantly associated with lower AL in-
dex after treatment. However, women showed higher anxiety levels in both, 
before (two-way ANOVA, p = 0.059) and after treatment (two-way ANOVA, 
p = 0.005), with a significantly better profile than men in many individual AL 
variables, particularly cardiovascular (systolic blood pressure), obesity (body 
mass index), and lipids (higher HDL levels). After treatment a higher reduc-
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tion of fibrinogen levels was found in men (two-way ANOVA, p = 0.02). 
Conclusions: In this preliminary analysis we described sex and age differenc-
es in psychiatry aspects and AL indexes in patients with general anxiety dis-
orders in the short-term treatment with alprazolam. These considerations re-
mark the need of pondering sex and age differences during the use of drugs 
for protracted periods. 
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1. Introduction 
To ensure a favorable assessment of the cumulative influence of stress on health, 
Seeman and Crimmins first developed Allostatic Load (AL) index in 1997 and 
proposed indicators for the functioning of the main potentially stress-affected 
systems [1] [2]. AL is currently considered a marker of cumulative biological risk 
and describes the additive effects of multiple clinical conditions that accelerate 
pathophysiology, augments the vulnerability to diseases and reduces resilience 
[2] [3] [4] [5] [6]. AL index includes different biological markers, involving car-
diovascular, metabolic and inflammatory markers [7].  
Anxiety disorders, particularly general anxiety disorders (GAD) are frequently 
associated with chronic stress and high levels of AL [8] [9] [10] [11] [12] and 
also neuroticism (a clinical condition well-known as a stress vulnerability factor 
defined as an exaggerated response to psychosocial stressors with intense emo-
tional reaction) [13], and mostly these factors interact increasing vulnerability to 
diseases, and reducing resilience [6]. Chronic stress mediated by hypothalam-
ic-pituitary-adrenal axis (HPA) hyperactivity, has been demonstrated to induce 
functionally-relevant effects on hippocampus and prefrontal cortex brain neuro-
plasticity, that may precipitate behavioural and cognitive impairments [9] [10] 
[14] [15]. Treatment of patients with GAD consists in psychotherapy; particu-
larly cognitive behavioral therapy is recommended [16]. Additionally, the use of 
drugs, most commonly antidepressants and/or benzodiazepines may be indi-
cated when symptoms are severe enough to induce a significant functional im-
pairment (National for Health and Clinical Excellence, UK guidelines) [16].  
Sex differences in stress response and stress-related diseases susceptibility, 
have been described in the literature with controversial results [3] [17]. Regard-
ing AL, clinical data has shown that women are less prone to cardiovascular dis-
ease and mortality than men before menopause, and metabolic and cardiovas-
cular risk factors seem to be higher among men [18] [19] [20]. Nevertheless, 
women showed higher levels of inflammatory markers, but with lower rates of 
increase in inflammation mediators with age [20]. This situation favoring wom-
en seem to be the opposite in reference to stress-related psychiatric diseases and 
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psychiatric disorders, which are more frequently observed and more severe in 
women than in men [3] [21]. Experimental studies demonstrated that neural 
remodelling pattern following chronic stress seem to be different between fe-
males and males suggesting sex differences in stress response with more intense 
compromise in females [3] [17]. Moreover, cognitive impairments associated to 
chronic stress are more intense in females [3] [17]. In addition to sex differences 
also age-dependent HPA axis dysregulation increase the vulnerability to 
stress-related disorders and contribute to cumulative AL [1] [7] [8] [12] [22] 
[23] [24] [25]. 
Despite the existence of theoretical explanations for sexual dimorphism and 
age effects in stress response; the empirical evidence is scarce, particularly 
among special populations with psychiatric disorder [19] [21] [26]. Accordingly, 
in this observational study we prospectively analyzed the clinical psychiatric 
profile and the AL index in a cohort of patients with GAD treated with alprazo-
lam (a positive allosteric modulator of GABA A receptor) during 12 weeks, and 
determined the effects of sex and age on allostatic load variables before and after 
treatment. 
2. Methods  
2.1. Patients 
This report is part of the preliminary results of the GEMA study protocol, which 
has been discussed in detail in a previous publication [27]. In this open and 
prospective study volunteer patients were recruited since September 2011 until 
May 2014, after signing the informed consent. Inclusion criteria were Hamilton 
Anxiety Rating (HAM-A)1 Scale [28] > 6, a minimum score of 18 points in the 
NEO-FFI neuroticism scale [29] and at least one positive criterion for AL load 
index modified from Seeman and Crimmins 2003 [1] (clinical manifestations 
were under personalized medical treatment and were stable). All patients had a 
normal performance in the Mini-Mental State Examination [30] with normal vi-
sion and hearing with or without the use of aids. All patients included had an 
urban style of life, living in Cordoba city and surroundings. In this study, clinical 
and allostatic load variables were explored at baseline (−1 week) and after treat-
ment (12 weeks). Patients were grouped according to sex (males/females) and 
age (< 50 years/≥ 50 years), being 50 years old the menopause mean age. 
Exclusion criteria were: patients with depression and/or other comorbid dis-
orders listed under axis I of the DSM-IV, (American Psychiatric Association, 
1994), patients taking a psychopharmacologic, sympathomimetic, corticosteroid 
or any other medication that might interact with alprazolam; patients who were 
allergic to drugs; with confirmed or suspected pregnancy; women likely to be-
come pregnant during the study; patients with an important clinical condition 
that required treatment modification and that might interfere with the study 
treatment or evaluation methods.  
 
 
1(HAM-A) Hamilton Anxiety Rating.  
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2.2. Psychiatric Assessment 
Anxiety assessment: All patients included in this study met criteria for general 
anxiety disorder codified in Axis I of DSM IV (American Psychiatric Associa-
tion) [31], and psychiatric assessment was determined by experimented clinical 
psychiatrists. In all patients the HAM-A [28] of 14 items was determined, (>6 
points indicated anxiety and ≥15 points indicated moderate to severe anxiety). 
For neuroticism assessment, the NEO-five factor inventory was applied. It 
measures personality factors related to neuroticism, extraversion, openness, 
kindness and responsibility [29]. 
2.3. Allostatic Load Determination and Cut off Points 
For measuring allostatic load index, 18 clinical and biochemical parameters were 
determined during the morning (10 ± 1 AM). One point was added for each ab-
normal parameter up or under the cut off points according to Crimmins and 
Seeman criteria modified (Crimmins et al. 2003) [1]: 1—Systolic blood pres-
sure >140 mmHg and/or; 2—diastolic pressure >90 mmHg; 3—BMI2 (body mass 
index) >25; 4—waist-hip ratio (indexes of adipose tissue deposition) more 
than >1 in men and >0.8 in women; 5—total cholesterol >200 mg/dl; 6—LDL 
(low density lipoprotein) >120 mg/dl; 7—HDL (high density lipoprotein) >37 
mg/dl; 8—total cholesterol/HDL ratio >3.5 mg/dl; 9—triglycerides >200 mg/dl; 
10—creatinine >1.2 mg/dl; 11—albumin <3.5 g/dl; 12—C-reactive protein 
(CRP) >7.1 mg/L; 13—fibrinogen >400 mg/dl; 14—glycated hemoglobin >6 mg/dl; 
15—salivary cortisol >32 nM; 16—salivary methoxy-hydroxy-phenylglycol 
(MHPG) (noradrenaline metabolite) >2750 nM; 17—serum dehydro-epi-an- 
drosterone (DHEA) <80 ng/ml in men and <35 ng/ml in women; 18—serum 
noradrenaline levels > 100 pg/ml. The study participants were evaluated prior to 
treatment (week-1) and after treatment initiation (week 12).  
2.4. General Conditions and Safety 
Additional assessments included respiratory function and laboratory tests. All 
patients have been warned about alprazolam’s depressant effects and the possible 
risks in activities that required alert. Alcohol consumption was not recom-
mended. Patients were also monitored to detect risk of suicide and/or overdose. 
All adverse events were monitored according to good clinical practice standards 
of the local regulatory authority; National Administration of Drugs, Foods and 
Medical Devices (ANMAT) and the Ministry of Health, Province of Córdoba. 
2.5. Treatment Instauration 
Patients admitted into the study were given alprazolam tablets (Alplax®, Gador 
SA, Buenos Aires; batch number 03730), in a flexible dosing regimen within 0.25 
to 1 mg t.i.d. (three times a day), which enabled the analysis of the dose-response 
relationship for the variables under investigation. Individual doses were deter-
 
 
2(BMI) Body mass index. 
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mined according to clinical criteria by the researcher responsible for each pa-
tient, and the lowest effective dose was administered in each case. Patient com-
pliance was assessed by monitoring salivary alprazolam levels and found to be 
satisfactory throughout the study in all cases. The alprazolam’s dosage schedule 
was maintained for 12 weeks. Subsequently, the investigator decided to continue 
or discontinue treatment. Laboratory tests were blinded to the researcher. Statis-
tics and graphs were obtained using a computational program for windows.  
2.6. Statistics  
Dispersion measures of quantitative variables were determined. Statistical signi-
ficance was considered at p < 0.05 (2-sided; 1-β power ≥ 0.80). The sample size 
was calculated in (n = 29 - 55) cases, with the aim to detect changes in variables 
higher than 25% with a 1-β power of 0 - 80 [27]. 
Spearman (non-parametric) and/or Pearson (parametric) tests were used to 
determine the correlation coefficient: r > 0.80 and p < 0.05 (2-sided) was consi-
dered as strong correlation and 0.50 < r < 0.80 and p < 0.05 (2-sided), was con-
sidered a moderate correlation [32]. For non-continuous variables Chi-square 
test and/or Fisher’s test was determined. To analyze sex and age factors effects 
on clinical and allostatic load parameters, a general univariant lineal model 
(two-way ANOVA) was applied for each allostatic load variable measured before 
and after treatment. Student’s t-test related variables were used to compare 
measures before and after treatment. Two-way ANOVA test was used to deter-
mine the effects of sex and age on the arithmetic differences determined after 
treatment for each AL parameter. Interactions between factors were also ana-
lyzed, and the effect size was calculated using the partial eta squared (hp2). 
Pearson/Spearman correlations were determined for continuous variables. 
2.7. Approval  
The protocol was evaluated and approved in accordance with the code of ethics 
of the World Medical Association (Declaration of Helsinki) and Clinical Practice 
guidelines in Argentina, by the Independent Ethics Committee of the Founda-
tion for Pharmacological Studies and Drugs, Buenos Aires, and then submitted 
to the national regulatory authority (ANMAT, Disposition #61409-8) and to the 
regulatory authority, under the Ministry of Health’s responsibility, Province of 
Córdoba (Dossier #1296). The trial is also registered at WHO (Word Health 
Organization)3, trial registration data set. Results were reported to the ANMAT, 
Argentine regulatory agency in accordance with regulations in force. All patients 
signed the informed consent form. 
3. Results  
In this observational study, 54 patients, 35 females (48.6 ± 11.7 years) and 19 
males (44.2 ± 12.8 years) with general anxiety disorder were included. Patients 
 
 
3(WHO) Word Health Organization. 
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were also grouped by age resulting in 28 patients with <50 years (60.7% females), 
and 26 ≥ 50 years (69.2% females). From this group 50 patients, 31 females and 
19 males completed the treatment period of 12 weeks. No serious adverse events 
were reported.  
Table 1 summarizes the clinical psychiatric variables and the total AL index. 
Women showed a different psychiatric profile with higher anxiety levels in the 
HAM-A at both, before and after treatment, but at the same time with a better 
profile in neuroticism scale showing higher scores in NEOFFI kindness before 
and after treatment. Additionally, HAM-A index improved in all groups after 12 
weeks of treatment (Student t test, p < 0.05). Younger patients (<50 years) but 
non-sex related factor were associated with significantly lower AL index after 
treatment. 
Table 2 summarizes the individual AL parameters. Women showed a signifi-
cantly better profile in many AL indexes, particularly in the cardiovascular ones, 
with lower systolic blood pressure, higher HDL levels and lower total cholesterol 
(Tch) and Tch/HDL ratio before and after treatment compared to men, without 
significant interactions with age-related factor (p > 0.05). Furthermore, women 
showed lower body mass index, lower waist-hip ratio, and lower creatinine levels 
before and after treatment and lower levels of triglycerides before treatment 
compared to men, without significant interactions with age-related factor.  
In a further analysis (Table 3), the univariate analysis for age and sex was 
calculated for the arithmetic differences observed after treatment in all AL pa-
rameters measured, and the student’s t-test for related variables was calculated 
for the mean of each variable measured. It can be noticed that a higher reduction 
of fibrinogen levels and Tch/HDL ratio was detected in men compared to wom-
en, without significant interactions with age-related factor, along with differenc-
es among pharmacological responses to alprazolam.  
Finally, Pearson correlations between AL and clinical variables were deter-
mined, and some findings were assessed regarding inflammatory markers. A low 
to moderate positive correlation between BMI and CRP was found in women 
before (r = 0.54, p = 0.001), and after treatment (r = 0.59, p = 0.001), while in 
men it was slightly lower (r = 0.48, p = 0.039) and (r = 0.45, p = 0.051) before 
and after treatment, respectively. Other correlations were lower and negative as 
the fibrinogen and Tch, (r = −0.46, p = 0.047) in men and (r = −0.48, p = 0.004) 
in women, observed before treatment, but not following treatment. In addition, 
only in women CRP negatively correlated with HDL (r = −0.36, p = 0.045), and 
fibrinogen negatively correlated with HDL (−0.40, p = 0.027). Additionally after 
treatment, a low to moderate negative correlation between CRP and plasmatic 
cortisol (r = −0.44, p = 0.015) was found in women, but not in men (r = −0.16, p 
= 0.504).  
4. Discussion  
These preliminary results regarding AL index distribution by sex and age in 
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Table 1. Comparison of clinical psychiatric assessments (Hamilton-Anxiety and NEOFFI 
scales) and total allostatic load index, in a sample of patients with anxiety disorders, 
neuroticism and allostatic load, clustered by sex and age groups (≥ 50 years; < 50 years), 
previous (basal) and after 12 weeks of alprazolam low dose treatment. 
Clinical 
Assessments 
(scores) 
Sex 
-------- 
Age 
n χ SD 
Two-way 
ANOVA 
F (df) 
= p value 
Partial eta 
squared 
(hp2) 
t-test 
(basal vs. 
w12 ) 
p value 
Hamilton Anxiety Scale (HAM-A) 
Basal 
Females 
Males 
35 31.7 10.2 3.7 (1.50) 
= 0.05 0.069 
 
19 28.2 6.4 
≥ 50 ys 
< 50 ys 
26 31.4 8.1 0.01 (1.50) 
= 0.97 0.001 28 30.9 8.3 
w12 
Females 
Males 
31 14.4 5.7 8.82 (1.46) 
= 0.005* 0.161 
0.001* 
19 9.4 5.8 0.001* 
≥ 50 ys 
< 50 ys 
24 13.1 6.4 0.03 (1.46) 
= 0.90 0.000 
0.001* 
26 11.9 6.1 0.001* 
NEOFFI Neuroticism 
Basal 
Females 
Males 
35 31.6 6.7 0.09 (1.50) 
= 0.75 0.002 
 
19 30.9 6.7 
≥ 50 ys 
< 50 ys 
26 30.5 6.02 0.34 (1.50) 
= 0.55 0.007 28 32.1 7.2 
w12 
Females 
Males 
31 29.2 7.3 0.44 (1.46) 
= 0.50 0.010 
0.021* 
19 28.3 7.2 0.085 
≥ 50 ys 
< 50 ys 
24 28.0 7.0 1.82 (1.46) 
= 0.18 0.038 
0.024* 
26 29.7 7.4 0.055 
NEOFFI Extroversion 
Basal 
Females 
Males 
35 25.2 8.9 0.59 (1.50) 
= 0.44 0.012 
 
19 23.5 6.8 
≥ 50 ys 
< 50 ys 
26 22.6 6.6 1.93 (1.50) 
= 0.17 0.037 28 26.4 9.1 
w12 
Females 
Males 
31 26.8 9.0 1.26 (1.46) 
= 0.27 0.027 
0.142 
19 24.3 7.5 0.577 
≥ 50 ys 
< 50 ys 
24 23.5 8.5 2.49 (1.46) 
= 0.12 
 
0.051 
0.448 
26 28.0 7.9 0.186 
NEOFFI Openness 
Basal 
Females 
Males 
35 25.7 7.8 0.04 (1.50) 
= 0.84 0.001 
 
19 26.2 5.5 
≥ 50 ys 
< 50 ys 
26 24.5 6.0 0.96 (1.50) 
= 0.33 0.019 28 27.1 7.7 
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Continued 
w12 
Females 
Males 
31 28.0 7.0 0.12 (1.46) 
= 0.73 0.003 
0.16 
19 27.5 6.9 0.121 
≥ 50 ys 
< 50 ys 
24 25.4 5.4 4.72 (1.46) 
= 0.035* 0.093 
0.49 
26 30.1 6.0 0.081 
NEOFFI Kindness 
Basal 
Females 
Males 
35 31.1 5.8 7.4 (1.50) 
= 0.009* 0.129 
 
19 26.7 5.3 
≥ 50 ys 
< 50 ys 
26 31.1 6.0 2.06 (1.50) 
= 0.15 0.040 28 28.1 5.6 
w12 
Females 
Males 
31 30.9 5.8 6.99 (1.46) 
= 0.01* 0.132 
0.85 
19 26.3 5.4 0.77 
≥ 50 ys 
< 50 ys 
24 31.0 5.8 3.36 (1.46) 
= 0.07 0.068 
0.98 
26 27.5 5.9 0.63 
NEOFFI Responsibility 
Basal 
Females 
Males 
35 29.5 7.8 0.20 (1.50) 
= 0.66 0.004 
 
19 28.2 8.3 
≥ 50 ys 
< 50 ys 
26 29.4 7.4 0.36 (1.50) 
= 0.55 0.007 28 28.6 8.5 
w12 
Females 
Males 
31 29.6 6.1 0.16 (1.46) 
= 0.69 0.003 
0.35 
19 30.1 7.8 0.068 
≥ 50 ys 
< 50 ys 
24 29.8 6.1 0.16 (1.46) 
= 0.69 0.004 
0.18 
26 29.8 7.3 0.210 
Total 
Allostatic Load Index 
Basal 
Females 
Males 
35 5.4 2.3 1.08 (1.50) 
= 0.30 0.021 
 
19 6.0 2.2 
≥ 50 ys 
< 50 ys 
26 6.1 1.8 3.31 (1.50) 
= 0.07 0.062 28 5.1 2.4 
w12 
Females 
Males 
31 4.6 2.5 2.13 (1.46) 
= 0.15 0.044 
0.013* 
19 5.4 1.9 0.118 
≥ 50 ys 
< 50 ys 
24 5.7 2.1 5.98 (1.46) 
= 0.02* 0.115 
0.056 
26 4.1 2.3 0.026* 
n: number of subjects per group; χ: average value; SD: standard deviation from mean; df: degrees of free-
dom, basal: week 0 of treatment, w12: week 12 of treatment, ys: years, vs: versus, *p < 0.05 (significant out-
come). 
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Table 2. Comparison of the individual components of the allostatic load index 
assessments, in a sample of patients with anxiety disorders, neuroticism and allostatic 
load, clustered by sex and age groups (≥ 50 years; < 50 years), previous (basal) and after 
12 weeks of alprazolam low dose treatment. See the cut off points for each variable in the 
text. 
Allostatic Load 
variables 
Sex 
---------- 
Age 
n χ SD 
Two-way ANOVA 
F (df) 
= p value 
Partial eta 
squared 
(hp2) 
Diastolic Blood Pressure (mmHg) 
Basal 
Females 
Males 
35 79.9 10.7 1.35 (1.50) 
= 0.25 0.069 19 83.7 12.9 
≥ 50 ys 
< 50 ys 
26 82.9 9.6 0.58 (1.50) 
= 0.44 0.01 28 79.6 13.1 
w12 
Females 
Males 
31 75.5 10.1 1.86 (1.46) 
= 0.17 0.03 19 79.5 9.0 
≥ 50 ys 
< 50 ys 
24 78.3  0.21 (1.46) 
= 0.64 0.005 26 75.8 10.1 
Systolic Blood Pressure (mmHg) 
Basal 
Females 
Males 
35 120.3 16.5 4.29 (1.50) 
= 0.04* 0.07 19 130.3 19.9 
≥ 50 ys 
< 50 ys 
26 126.9 17.3 1.74 (1.50) 
= 0.19 0.03 28 120.9 18.9 
w12 
Females 
Males 
31 114.7 12.8 4.36 (1.46) 
= 0.04* 0.08 19 121.6 12.7 
≥ 50 ys 
< 50 ys 
24 121.7 14.0 4.78 (1.46) 
= 0.03* 0.09 26 113.3 10.9 
Body Mass Index 
Basal 
Females 
Males 
35 25.4 4.9 6.91 (1.50) 
= 0.01* 0.12 19 29.6 6.8 
≥ 50 ys 
< 50 ys 
26 27.9 3.9 1.04 (1.50) 
= 0.31 0.02 28 26.0 7.3 
w12 
Females 
Males 
31 24.8 5.3 7.03 (1.46) 
= 0.01* 0.13 19 29.2 6.4 
≥ 50 ys 
< 50 ys 
24 27.3 4.4 0.91 (1.46) 
= 0.34 0.02 26 25.7 7.2 
Waist-hip ratio 
Basal 
Females 
Males 
35 0.8 0.1 43.4 (1.50) 
= 0.001* 0.46 19 1.0 <0.1 
≥ 50 ys 
< 50 ys 
26 0.9 0.1 1.13 (1.50) 
= 0.29 0.02 28 0.9 0.1 
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Continued 
w12 
Females 
Males 
31 0.8 0.1 41.95 (1.46) 
= 0.001* 0.47 19 1.0 0.1 
≥ 50 ys 
< 50 ys 
24 0.9 0.1 2.97 (1.46) 
= 0.09 0.06 26 0.9 0.1 
Total Cholesterol (mg/dl) 
Basal 
Females 
Males 
35 225.3 41.4 3.18 (1.50) 
= 0.08 0.06 19 204.3 41.0 
≥ 50 ys 
< 50 ys 
26 220.9 47.5 0.01 (1.50) 
= 0.90 0.001 28 215.0 37.0 
w12 
Females 
Males 
31 215.2 44.8 2.33 (1.46) 
= 0.13 0.0 19 193.6 46.2 
≥ 50 ys 
< 50 ys 
24 215.0 51.7 0.94 (1.46) 
= 0.33 0.02 26 199.5 39.7 
Cholesterol LDL (mg/dl) 
Basal 
Females 
Males 
35 136.8 31.7 1.39 (1.50) 
= 0.24 0.02 19 126.2 40.0 
≥ 50 ys 
< 50 ys 
26 131.9 35.4 0.39 (1.50) 
= 0.53 0.008 28 134.2 34.9 
w12 
Females 
Males 
31 126.4 33.2 0.02 (1.46) 
= 0.86 0.001 19 124.5 39.2 
≥ 50 ys 
< 50 ys 
24 127.1 39.2 0.03 (1.46) 
= 0.86 0.001 26 124.4 31.8 
Cholesterol HDL (mg/dl) 
Basal 
Females 
Males 
35 61.4 16.7 17.57 (1.50) 
= 0.001* 0.26 19 43.0 10.3 
≥ 50 ys 
< 50 ys 
26 57.3 16.4 0.55 (1.50) 
= 0.46 0.01 28 52.7 17.8 
w12 
Females 
Males 
31 61.1 15.9 11.60 (1.46) 
= 0.001* 0.20 19 45.5 13.0 
≥ 50 ys 
< 50 ys 
24 57.0 16.6 0.63 (1.46) 
= 0.43 0.01 26 53.5 16.7 
Ratio TCh/HDL 
Basal 
Females 
Males 
35 3.9 1.3 6.74 (1.50) 
= 0.01* 0.11 19 5.0 1.3 
≥ 50 ys 
< 50 ys 
26 4.1 1.1 0.91 (1.50) 
= 0.34 0.01 28 4.5 1.6 
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w12 
Females 
Males 
31 3.8 1.2 3.72 (1.46) 
= 0.06 0.07 19 4.4 1.1 
≥ 50 ys 
< 50 ys 
24 4.0 1.2 0.001 (1.46) 
= 0.98 0.001 26 4.0 1.2 
Triglycerides (mg/dl) 
Basal 
Females 
Males 
35 142.0 87.1 4.53 (1.50) 
= 0.03* 0.08 19 195.4 98.1 
≥ 50 ys 
< 50 ys 
26 168.4 98.4 0.75 (1.50) 
= 0.38 0.01 28 153.7 90.4 
w12 
Females 
Males 
31 137.8 79.96 1.74 (1.46) 
= 0.19 0.036 19 162.3 66.12 
≥ 50 ys 
< 50 ys 
24 172.3 86.12 4.85 (1.46) 
= 0.03* 0.09 26 123.9 55.73 
Creatinine (mg/dl) 
Basal 
Females 
Males 
35 0.7 0.1 56.09 (1.50) 
= 0.001* 0.52 19 1.0 0.2 
≥ 50 ys 
< 50 ys 
26 0.8 0.2 1.79 (1.50) 
= 0.18 0.03 28 0.8 0.2 
w12 
Females 
Males 
31 0.7 0.1 39.92 (1.46) 
= 0.001* 0.46 19 0.9 0.1 
≥ 50 ys 
< 50 ys 
24 0.8 0.8 0.005 (1.46) 
= 0.94 0.001 26 0.8 0.2 
Albumin (g/dl) 
Basal 
Females 
Males 
35 4.6 0.4 0.71 (1.50) 
= 0.40 0.01 19 4.5 0.4 
≥ 50 ys 
< 50 ys 
26 4.5 0.4 1.70 (1.50) 
= 0.19 0.03 28 4.60 0.3 
w12 
Females 
Males 
31 4.54 0.46 0.40 (1.46) 
= 0.53 0.009 19 4.5 0.5 
≥ 50 ys 
< 50 ys 
24 4.5 0.5 0.35 (1.46) 
= 0.55 0.008 26 4.5 0.4 
C Reactive Protein (mg/L) 
Basal 
Females 
Males 
35 2.2 3.7 0.15 (1.50) 
= 0.70 0.003 19 1.8 2.7 
≥ 50 ys 
< 50 ys 
26 1.9 2.7 0.08 (1.50) 
= 0.78 0.002 28 2.3 3.9 
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w12 
Females 
Males 
31 1.6 2.3 0.13 (1.46) 
= 0.71 0.003 19 1.5 1.4 
≥ 50 ys 
< 50 ys 
24 1.5 1.9 0.20 (1.46) 
= 0.65 0.004 26 1.6 2.1 
Fibrinogen (mg/dl) 
Basal 
Females 
Males 
35 394.4 139.8 0.29 (1.50) 
= 0.59 0.006 19 414.4 107.2 
≥ 50 ys 
< 50 ys 
26 420.1 126.5 0.51 (1.50) 
= 0.47 0.01 28 384.1 130.4 
w12 
Females 
Males 
31 424.3 152.2 0.70 (1.46) 
= 0.40 0.01 19 383.5 93.6 
≥ 50 ys 
< 50 ys 
24 418.8 133.0 0.19 (1.46) 
= 0.66 0.004 26 399.6 135.7 
Glycated Hemoglobin (mg/dl) 
Basal 
Females 
Males 
35 6.0 0.8 0.70 (1.50) 
= 0.40 0.01 19 5.8 0.5 
≥ 50 ys 
< 50 ys 
26 6.0 0.7 0.19 (1.50) 
= 0.66 0.004 28 5.8 0.7 
w12 
Females 
Males 
31 5.7 0.6 0.46 (1.46) 
= 0.50 0.01 19 5.8 0.6 
≥ 50 ys 
< 50 ys 
24 5.9 0.7 3.69 (1.46) 
= 0.06 0.07 26 5.6 0.4 
Salivary Cortisol (nM) 
Basal 
Females 
Males 
35 13.0 9.9 0.27 (1.50) 
= 0.60 0.005 19 13.8 5.3 
≥50 ys 
< 50 ys 
26 12.0 7.3 0.04 (1.50) 
= 0.85 0.001 28 14.5 9.4 
w12 
Females 
Males 
31 9.9 7.5 0.09 (1.46) 
= 0.76 0.002 19 10.4 8.7 
≥ 50 ys 
< 50 ys 
24 10.0 8.8 0.05 (1.46) 
= 0.83 0.001 26 10.2 7.0 
Salivary MHPG (nM) 
Basal 
Females 
Males 
35 1655.8 1516.3 0.56 (1.50) 
= 0.45 0.01 19 2126.6 2638.7 
≥ 50 ys 
< 50 ys 
26 1700.3 1515.9 0.19 (1.50) 
= 0.66 0.004 28 1933.9 2341.6 
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w12 
Females 
Males 
31 641.7 360.8 0.03 (1.46) 
= 0.87 0.001 19 620.5 247.1 
≥ 50 ys 
< 50 ys 
24 647.7 409.7 0.13 (1.46) 
= 0.71 0.001 26 620.7 213.5 
Serum DHEA (ng/ml) 
Basal 
Females 
Males 
35 77.2 58.0 0.38 (1.50) 
= 0.538 0.008 19 90.8 49.8 
≥ 50 ys 
< 50 ys 
26 60.6 40.6 7.83 (1.50) 
= 0.007* 0.13 28 101.8 60.0 
w12 
Females 
Males 
31 69.1 56.6 1.63 (1.46) 
= 0.20 0.03 19 93.1 53.7 
≥ 50 ys 
< 50 ys 
24 51.5 38.5 11.56 (1.46) 
= 0.001* 0.20 26 102.9 59.3 
Serum NA (pg/ml) 
Basal 
Females 
Males 
35 239.0 141.8 0.69 (1.50) 
= 0.41 0.01 19 260.7 145.6 
≥ 50 ys 
< 50 ys 
26 245.5 150.8 0.77 (1.50) 
= 0.38 0.01 28 247.7 136.3 
w12 
Females 
Males 
31 225.5 123.6 0.18 (1.46) 
= 0.67 0.004 19 207.9 68.4 
≥ 50 ys 
< 50 ys 
24 226.8 112.3 0.52 (1.46) 
= 0.47 0.01 26 211.5 100.6 
n: number of subjects per group; χ: average value; SD: standard deviation from mean; df: degrees of free-
dom, basal: week 0 of treatment, w12: week 12 of treatment, ys: years, MHPG: Methoxy-hydroxy-phenylglycol, 
DHEA: dehidro-epiandrosterone, NA: noradrenaline, *p < 0.05 (significant outcome). 
 
Table 3. Differences in the total allostatic load index and in its individual variables in a 
sample of patients with anxiety disorders, neuroticism and allostatic load, clustered by 
sex and age groups (≥ 50 years; < 50 years), previous (basal) and after 12 weeks of 
alprazolam low dose treatment. The figures (χ and SD) show the arithmetic difference 
between the values before and after treatment. Two-way ANOVA test the significance 
between groups (by sex or age), and test-t test the difference between before and after for 
each variable.  
Arithmetic  
difference 
after treatment 
Sex 
---------- 
Age 
n χ SD 
Two-way ANOVA 
F (df) 
= p value 
Partial eta 
squared 
(hp2) 
Total Allostatic 
Load Index 
(score) 
Females 
Males 
31 −0.74 1.56 0.13 (1.46) 
= 0.72 0.069 19 −0.57 1.53 
≥ 50 ys 
< 50 ys 
24 −0.54 1.31 0.11 (1.46) 
= 0.74 0.002 26 −0.81 1.74 
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Diastolic Blood 
Pressure 
(mmHg) 
Females 
Males 
31 −4.26 9.05 0.01 (1.46) 
= 0.93 0.001 19 −4.21 16.18 
≥ 50 ys 
< 50 ys 
24 −5.00 10.89 0.37 (1.46) 
p = 0.54 0.008 26 −3.57 12.97 
Systolic Blood 
Pressure 
(mmHg) 
Females 
Males 
31 −8.68 16.98 0.46 (1.46) 
= 0.42 0.01 19 −5.32 14.37 
≥ 50 ys 
< 50 ys 
24 −6.66 15.01 0.07 (1.46) 
= 0.78 0.002 26 −6.53 15.92 
Body Mass Index 
Females 
Males 
31 −0.41 1.65 0.00 (1.46) 
= 0.99 0.001 19 −0.43 1.19 
≥ 50 ys 
< 50 ys 
24 −0.58 1.88 0.18 (1.46) 
= 0.67 0.004 26 −0.27 1.00 
Waist−hip ratio 
Females 
Males 
31 0.002 0.03 0.15 (1.46) 
= 0.69 0.003 19 0.005 0.04 
≥ 50 ys 
< 50 ys 
24 0.009 0.03 1.20 (1.46) 
= 0.27 0.02 26 −0.002 0.04 
Total Cholesterol 
(mg/dl) 
Females 
Males 
31 −12.48 35.70 0.09 (1.46) 
= 0.76 0.002 19 −10.68 37.44 
≥ 50 ys 
< 50 ys 
24 −6.70 36.49 1.14 (1.46) 
= 0.29 
 
0.02 26 −16.50 35.59 
Cholesterol 
LDL 
(mg/dl) 
 
Females 
Males 
31 −11.97 30.05 1.97 (1.46) 
= 0.16 0.04 19 −1.63 23.34 
≥ 50 ys 
< 50 ys 
24 −8.04 27.90 0.61 (1.46) 
= 0.43 0.01 26 −9.57 28.28 
Cholesterol 
HDL 
(mg/dl) 
Females 
Males 
31 −1.61 12.55 1.85 (1.46) 
= 0.17 0.03 19 2.52 8.60 
≥ 50 ys 
< 50 ys 
24 −0.54 10.01 0.03 (1.46. 
= 0.85 0.001 26 0.42 12.56 
Ratio TCh/HDL 
Females 
Males 
31 −0.14 0.64 3.54 (1.46) 
=0.06 0.07 19 −0.53 0.73 
≥ 50 ys 
< 50 ys 
24 −0.06 0.56 3.41 (1.46) 
= 0.07 
 
0.06 26 −0.49 0.75 
Triglycerides 
(mg/dl) 
Females 
Males 
31 −0.51 74.00  
2.52 (1.46) 
= 0.12 
0.05 
19 −33.10 65.99 
≥ 50 ys 
< 50 ys 
24 3.50 73.97 1.10 (1.46) 
= 0.30 0.02 26 −28.03 68.38 
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Creatinine 
(mg/dl) 
Females 
Males 
31 −0.02 0.15 0.16 (1.46) 
= 0.69 0.003 19 −0.03 0.11 
≥ 50 ys 
< 50 ys 
24 −0.04 0.11 0.96 (1.46) 
= 0.33 0.02 26 −0.02 0.15 
Albumin 
(gdl) 
Females 
Males 
31 −0.07 0.55 0.04 (1.46) 
= 0.84 0.001 19 −0.05 0.54 
≥ 50 ys 
< 50 ys 
24 −0.05 0.53 0.11 (1.46) 
= 0.73 0.003 26 − 0.07 0.57 
C Reactive 
Protein 
(mg/L) 
Females 
Males 
31 −0.56 2.44 0.03 (1.46) 
= 0.85 0.001 19 −0.35 2.33 
≥ 50 ys 
< 50 ys 
24 −0.42 2.35 0.03 (1.46) 
= 0.84 0.001 26 −0.54 2.45 
Fibrinogen 
(mg/dl) 
Females 
Males 
31 32.58 107.45 5.38 (1.46), 
= 0.02* 0.10 19 −30.89 79.57 
≥ 50 ys 
< 50 ys 
24 −5.62 116.87 1.42(1.46), 
= 0.23 0.03 26 21.47 85.91 
Glycated 
Hemoglobin 
(mgdl) 
Females 
Males 
31 −0.24 0.71 1.72 (1.46), 
= 0.19 0.03 19 0.01 0.76 
≥ 50 ys 
< 50 ys 
24 −0.05 0.73 1.09(1.46) 
= 0.30 0.02 26 −0.22 0.74 
Salivary Cortisol 
(nM) 
Females 
Males 
31 −3.82 5.31 0.01 (1.46) 
= 0.90 0.001 19 −3.43 11.19 
≥50 ys 
< 50 ys 
24 −2.34 9.26 0.48(1.46), 
= 0.49 0.01 26 −4.90 6.48 
Salivary MHPG 
(nM) 
Females 
Males 
31 −1103.93 1455.89 0.36 (1.46), 
= 0.54 0.006 19 −1506.05 2646.08 
≥ 50 ys 
< 50 ys 
24 −1104.54 1511.31 0.27 (1.46), 
= 0.60 0.006 26 −1397.23 2348.81 
Serum DHEA 
(ng/ml) 
Females 
Males 
31 −10.35 25.14 3.34 (1.46), 
= 0.07 0.06 19 2.27 15.78 
≥50 ys 
< 50 ys 
24 −8.71 26.15 0.65 (1.46), 
= 0.042* 0.01 26 −2.63 19.11 
Serum NA 
(pg/ml) 
Females 
Males 
31 −22.20 158.95 0.773 (1.46), 
= 0.38 0.017 19 −52.83 113.66 
≥ 50 ys 
< 50 ys 
24 −29.88 134.47 0.110(1.46), 
= 0.74 0.002 26 −37.49 152.96 
n: number of subjects per group; χ: average value; SD: standard deviation from mean; df: degrees of free-
dom, basal: week 0 of treatment, w12: week 12 of treatment, ys: years, MHPG: Methoxy-hydroxy-phenylglycol, 
DHEA: dehidro-epiandrosterone, NA: noradrenaline, *p < 0.05 (significant outcome). 
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patients with GAD, are consistent with the literature review comparing sex effect 
on metabolic syndrome and/or on cardiovascular risk in general populations [7] 
[33]. However, there are only a few studies applying the AL index in patients 
with psychiatric disorders [19] [21]. 
As well as younger patients (< 50 years) but non-sex related factor, were sig-
nificantly associated with lower total AL index after treatment, in this study 
many differences were found regarding sex. Women showed higher anxiety le-
vels before and after treatment. It has been postulated that women may be more 
vulnerable and/or more exposed to chronic stress, to explain the higher inci-
dence and severity of stress-related psychiatric disorders such as depression 
and/or anxiety [25] [34]. It has been well established that anxiety, depression 
and posttraumatic stress disorders, are highly influenced by sex and gonadal 
hormones [26] [35]. Regarding anxiety disorders, panic disorder is more com-
mon in women than in men, and females demonstrated a greater stress response 
[36]. Moreover, posttraumatic stress disorders are more frequently diagnosed 
among women [37]. In this study we found that anxiety levels were higher 
among women, suggesting a more severe psychiatric symptomatology. Never-
theless, women also showed a higher score in kindness in the neuroticism scale, 
which may constitute a more protective trait of personality.  
Oppositely to psychiatric aspects, women showed a better AL profile among 
some individual allostatic variables, including cardiovascular, metabolic and ob-
esity risk variables. These findings are consistent with other studies that com-
pared sex differences analyzing cardiovascular risk factors and/or metabolic 
syndrome in general populations [19] [20] [36]. Males disadvantages for AL re-
lated pathologies, specially cardiovascular diseases, have been frequently ob-
served across human populations; however, it is also well known that the sex gap 
is more pronounced in young adults and decreases in the postmenopausal stage 
coinciding with female fecundity decline [19] [20] [35]. Regarding this finding, 
in this study we grouped patients according to age with the cut off at 50 years to 
differentiate menopause factor. Nonetheless, there are some studies that showed 
higher inflammatory markers such as CRP levels with an inflammatory over re-
sponse among women [19] [20] [38]. Similarly, in this study, women showed a 
better profile before and after treatment in cardiovascular and obesity factors but 
treatment seemed to bring a greater benefit to men by reducing both cholesterol 
ratio and fibrinogen, suggesting differences in treatment response. Furthermore, 
in women but not in men, a negative correlation between CRP levels with plas-
matic cortisol levels after treatment was reported, suggesting a possible differ-
ence in the anti-inflammatory actions of cortisol regarding sex. 
In this analysis, no differences between sex and age were observed regarding 
MHPG, (the principal noradrenergic metabolite and a biological marker of an-
xiety and chronic stress). MHPG was significantly reduced after treatment in all 
grouped patients with GAD. Similarly to our results, other studies reported vari-
ations in MHPG in patients with anxiety disorders [9] [39] [40]. In this study, 
we found a progressive reduction in salivary MHPG levels during 12 weeks of 
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treatment without tolerance to this effect. Other researchers determined lower 
salivary levels of MHPG in anxious patients treated with alprazolam [9] [39] [40] 
and in normal subjects who received the drug [41]. Additionally experimental 
data has suggested that the response of CNS (Central Nervous System) amplifies 
the emotional response, and anxiety can be particularly regarded as an undiffe-
rentiated form of fear or rage discharged by noradrenaline [42].  
This study showed blood pressure decay that returned to more normal levels 
with an additional reduction of anxiety and MHPG levels. Anxiety by itself has 
been proposed as an important factor involved in blood pressure elevation me-
diated by catecholamines and benzodiazepines, and particularly alprazolam has 
demonstrated anti-hypertensive pleiotropic properties especially in acute inter-
vention and in patients with high blood pressure without affecting the heart rate 
[43] [44]. In relation to this finding a lower blood pressure was detected (systolic 
and diastolic in women, and only systolic in men), following 12 weeks of alpra-
zolam treatment. It has been suggested that alprazolam in contrast with other 
anxiolytics as lorazepam has an additional suppression effect on the adrenome-
dullary system reducing the sympathetic discharge with lower plasma catecho-
lamine’s concentrations during exercise, stress, and throughout mental load 
(performing a cognitive test) [44] [45]. The high-potency benzodiazepine alpra-
zolam (a triazolo-benzodiazepine), leads to a positive allosteric modulation of 
GABA-A receptor with an additional indirect activity through 5-HT1A seroto-
ninergic receptors. These mechanisms are involved in the regulation of the 
hyperactive NA pathways inducing a reduction of noradrenergic system. It has 
been proposed that alprazolam administered at low doses may cause less impact 
on cognitive functions due to the shorter action compared to other benzodiaze-
pines [46] [47]. Notwithstanding, the risk of inducing pharmacological depen-
dence and/or other cognitive adverse events should be considered with a subse-
quent continuous monitoring [46] [48]. On the other side, chronic stress impairs 
cognitive function and decreases the likelihood of a prompt response to psycho-
therapy with the ensuing negative impact on quality of life [6].  
Limitations of this study must be mentioned: Neither placebo nor untreated 
groups were included; since it is not acceptable for phase IV trials to include this 
type of highly symptomatic patients, and hence, it was necessary to administer 
the active drug to the entire sample and according to demand. The fact is passa-
ble for being a preliminary trial conducted to explore a concept and the overall 
safety. Controlled studies will be performed in the coming steps and different 
goals. In this study we did not report the cognitive variables (described in the 
original protocol and still under analysis) [27], which are planned for future 
evaluation. Furthermore, as a significant reduction in the total AL index was ob-
served and many AL variables were significantly reduced after treatment, in this 
open study other non-pharmacological factors may also be considered to be in-
teracting during treatment. Therefore, we cannot attribute the observations to a 
single drug effect. 
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5. Conclusion 
In this preliminary study we described sex and age differences in clinical psy-
chiatric variables and parameters of AL index measured in patients with general 
anxiety disorders treated with alprazolam. These observations were scarce in the 
literature and will allow us to continue studying the impact of sex and age dif-
ferences during the use of drugs for more protracted periods.  
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